Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 844-848

  Culine, Stéphane ^a   El Demery, Mounira ^a   Lamy, Pierre Jean ^a   Iborra, François ^b   Avancès, Christophe ^c   Pinguet, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

^b CLINIQUE DU PARC   (France)

^c Clinique Kennedy   (France)

Author keywords

carcinoma; chromogranin A; neuroendocrine; phosphopyruvate hydratase; prostate; prostatic neoplasms

Indexed keywords

ANALGESIC AGENT; ANDROGEN; BIOLOGICAL MARKER; CHROMOGRANIN; CISPLATIN; DOCETAXEL; ERYTHROPOIETIN; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; NEUROENDOCRINE SPECIFIC PROTEIN; NEURON SPECIFIC ENOLASE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE SYSTEM; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SENSORY NEUROPATHY; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATROPINE; CHROMOGRANIN A; CISPLATIN; HUMANS; MALE; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547786581     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.044     Document Type: Article

References (19)

1. Loblaw D.A., Mendelson D.S., Talcott J.A., Virgo K.S., Somerfield M.R., Ben-Josef E., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 (2004) 2927
2. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
3. Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147
4. Mitry E., Baudin E., Ducreux M., Sabourin J.C., Rufié P., Aparicio T., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81 (1999) 1351
5. Fjällskog M.L.H., Granberg D.P.K., Welin S.L.V., Eriksson C., Oberg K.E., Janson E.T., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 (2001) 1101
6. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205
7. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
8. Hahn N.M., Marsh S., Fisher W., Langdon R., Zon R., Browning M., et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 12 (2006) 6094
9. Ferrero J.M., Chamorey E., Oudard S., Dides S., Lesbats G., Cavaglione G., et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 107 (2006) 738
10. Kolodziej M., Neubauer M.A., Rousey S.R., Pluenneke R.E., Perrine G., Mull S., et al. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 5 (2006) 155
11. Berruti A., Dogliotti L., Mosca A., Bellina M., Mari M., Torta M., et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88 (2000) 2590
12. Roudier M.P., True L.D., Higano C.S., Vesselle H., Ellis W., Lange P., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34 (2003) 646
13. Shah R.B., Mehra R., Chinnaiyan A.M., Shen R., Ghosh D., Zhou M., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64 (2004) 9209
14. Cussenot O., Villette J.M., Valeri A., Cariou G., Desgrandchamps F., Cortesse A., et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155 (1996) 1340
15. Angelsen A., Syversen U., Haugen O.A., Stridsberg M., Mjolnerod O.K., and Waldum H.L. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?. Prostate 30 (1997) 1
16. Bonkhoff H., Stein U., and Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 26 (1995) 167
17. Roudier M.P., True L.D., Vessella R.L., and Higano C.S. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 57 (2004) 321
18. Angelsen A., Syversen U., Stridsberg M., Haugen O.A., Mjolnerod O., and Waldum H.L. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 30 (1997) 110
19. Ahel M.Z., Kovacic K., Kraljic I., and Tarle M. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 21 (2001) 1475